Per-Ulf Tunn

Dr. Per-Ulf Tunn


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SSSheila Terwisscha van Scheltinga
Sheila Terwisscha van Scheltinga
TRTimothy Rogers
Timothy Rogers
NSNaima Smeulders
Naima Smeulders
FCFederica De Corti
Federica De Corti
Florent GuérinFlorent Guérin
Florent Guérin
JMJohannes H.M. Merks
Johannes H.M. Merks
Although survival after rhabdosarcoma treatment has improved over the years, one third of patients still develop locoregional relapse. This review aims to highlight developments pertaining to staging and local treatment of specific RMS tumor sites, including head and neck, chest/trunk, bladder-prostate, female genito-urinary, perianal, and extremity sites.

27 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
RFRaphaela Fritsche
Raphaela Fritsche
YGYoann Gloaguen
Yoann Gloaguen
MKMarieluise Kirchner
Marieluise Kirchner
PMPhilipp Mertins
Philipp Mertins
PTPer-Ulf Tunn
Per-Ulf Tunn
KJKirwan Jennifer
Kirwan Jennifer
Osteosarcoma (OS) is a primary malignant bone tumor and OS metastases are mostly found in the lung. The limited understanding of the biology of metastatic processes in OS limits the ability for effective treatment. Alterations to the metabolome and its transformation during metastasis aids the understanding of the mechanism and provides information on treatment and prognosis. The current study intended to identify metabolic alterations during OS progression by using a targeted gas chromatography mass spectrometry approach. Using a female OS cell line model, malignant and metastatic cells increased their energy metabolism compared to benign OS cells. The metastatic cell line showed a faster metabolic flux compared to the malignant cell line, leading to reduced metabolite pools. However, inhibiting both glycolysis and glutaminolysis resulted in a reduced proliferation. In contrast, malignant but non-metastatic OS cells showed a resistance to glycolytic inhibition but a strong dependency on glutamine as an energy source. Our in vivo metabolic approach hinted at a potential sex-dependent metabolic alteration in OS patients with lung metastases (LM), although this will require validation with larger sample sizes. In line with the in vitro results, we found that female LM patients showed a decreased central carbon metabolism compared to metastases from male patients.

28 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CSChristine Schwering
Christine Schwering
MNMaya Niethard
Maya Niethard
GGGeorg Gosheger
Georg Gosheger
Maria Anna SmolleMaria Anna Smolle
Maria Anna Smolle
Frank TraubFrank Traub
Frank Traub
DADimosthenis Andreou
Dimosthenis Andreou
Recent retrospective studies suggested that early postoperative infections might be associated with a survival benefit for extremity osteosarcoma patients, but the reported results have been conflicting. The files of 437 patients with a newly diagnosed, high-grade osteosarcoma of the extremities treated at 5 referral centers in Germany and Austria between 1989 and 2016 were retrospectively evaluated. All patients underwent multi-agent chemotherapy and limb-sparing tumor excision, followed by endoprothetic replacement. We used the Kaplan–Meier method to calculate survival curves, which we compared with the log-rank test. With a median follow-up of 100 months (interquartile range, 49–155 months), local recurrence (LR) probability, event-free survival (EFS), and disease-specific survival (DSS) after 5 years in this selected patient cohort amounted to 5%, 67%, and 79%, respectively, and 46 patients (10.5%) developed an early postoperative infection. We found no significant differences in LR, EFS, or DSS between patients with and without early infections, and there were no differences in known prognostic factors between the two groups. However, in subgroup analyses patients with a poor response to neoadjuvant chemotherapy and an early infection had a better DSS compared to patients without early infections (93% vs. 62% after 5 years, p = 0.044). Provided that our findings can be validated in separate patient cohorts, we believe that patient outcome after adjuvant immunomodulatory treatments in osteosarcoma patients should be evaluated and reported separately for good and poor responders to neoadjuvant chemotherapy in future studies.

16 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MNMaya Niethard
Maya Niethard
HFHeilwig Fischer
Heilwig Fischer
BGBernhard Gaßmann
Bernhard Gaßmann
LHLyubomir Haralambiev
Lyubomir Haralambiev
ATAlexander Tipp
Alexander Tipp
PTPer-Ulf Tunn
Per-Ulf Tunn
Background: Isolated limb perfusion (ILP) for soft tissue sarcomas (STS) is usually performed with tumor necrosis factor alpha (TNF-α) and melphalan. ILP regularly leads to a total blood loss (BLt) of 1.5–2 L/patient. Blood inflow from the central blood circulation to the limb is influenced by unstable pressure gradients and pain reactions after the administration of melphalan. With perioperative regional anesthesia (RA), pain levels can be reduced, and the pressure gradient stabilized resulting in a reduced BLt. The aim of this study was to compare the BLt with and without RA in patients with ILP during circulation of drugs. Methods: Patients were treated according to the following protocol: After the establishment of limb circulation, ILP was started with the administration of TNF-α. Half the dose of melphalan was given as a bolus after 30 min, and the remaining dose was continuously administered in the following 30 min. The extremity was washed out after 90 min. ILP with perioperative RA (supraclavicular plexus block/peridural catheter) was performed prospectively in 17 patients and compared to a matched retrospective control group of 17 patients without RA. BLt was documented and perioperative anesthesiological data were analyzed for response rates after the application of melphalan (RaM). Results: BLt and RaM tended to be lower for the intervention group with RA if compared to the control group without RA in all analyses. The trend of lower BLt and RaM in ILP with RA was more pronounced for the upper extremity compared to the lower extremity. Results were not statistically significant. Conclusion: These findings indicate that the use of RA can help to stabilize hemodynamic anesthetic management and reduce the BLt in ILP, especially during perfusion of the upper extremities.

24 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MNMaya Niethard
Maya Niethard
CKCarolin Knebel
Carolin Knebel
ALAndreas Leithner
Andreas Leithner
PTPer-Ulf Tunn
Per-Ulf Tunn
JSJanosch Schoon
Janosch Schoon
DADimosthenis Andreou
Dimosthenis Andreou
Primary leiomyosarcoma of bone (LMSoB) is extremely rare, comprising only <0.7% of primary malignant bone tumors, and is therefore considered an ultra-rare tumor entity. There is currently no consensus as to whether therapeutic strategies should be based on the biological characteristics of soft tissue leiomyosarcoma or on primary tumor localization in the bone. The use of perioperative chemotherapy and its effectiveness in this rare tumor entity remains unclear. We aimed to evaluate the impact of different treatment approaches in a multicenter setting with a total of 35 patients included. The 5-year overall survival (OS) was 74%. Patients with localized disease undergoing surgery had a significantly higher 5-year OS compared to patients who did not undergo surgical treatment (82% vs. 0%, p = 0.0015). Axial tumor localization was associated with worse event-free survival (EFS) probability (p < 0.001) and OS (p = 0.0082). A high proportion of our patients developed secondary metastases. Furthermore, the perioperative chemotherapy protocols applied to our patients were not associated with an improved EFS or OS. Therefore, the benefit of perioperative chemotherapy in LMSoB needs to be further investigated, and the choice of agents still needs to be clarified.

11 December 2020 in Der Onkologe
Verified
Journal Article
Closed access
PDF file
PTPer-Ulf Tunn
Per-Ulf Tunn
MKManoj Kakkassery
Manoj Kakkassery
PRPeter Reichardt
Peter Reichardt